Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cardiac biopsies from patients with ICI myocarditis reveal myocardial infiltration primarily by T cells.
“Cardiac biopsies from patients with ICI myocarditis revealed myocardial infiltration primarily by T cells”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [157]
The case report states that a myocardial biopsy from one patient with nivolumab-associated myocarditis showed lymphocytic infiltration predominantly by CD8-positive T cells. It does not establish that cardiac biopsies from patients with ICI myocarditis generally show this pattern. (LLM, conf=0.87)
Experimental — accuracy not yet measuredICI myocarditis may occur following ICI treatment in patients with cancer.
“one of the best examples of drug-induced lymphocytic myocarditis is ICI myocarditis, which may occur following ICI treatment in patients with cancer.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [157]
T cells may play a role in driving the pathogenesis of ICI myocarditis.
“suggesting a potential role of T cells in driving the pathogenesis of this condition.”
From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 320 · see citing works
PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288 · see citing works
Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200 · see citing works
Katano, H., Kano, M., Nakamura, T., Kanno, T., Asanuma, H., & Sata, T. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21962 · Cited by 64 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608 · see citing works
Palaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535 · see citing works
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247 · see citing works
Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178 · see citing works
Cardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 160 · see citing works
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137 · see citing works
Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 123 · see citing works
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 123 · see citing works
Uversky, V. N., Redwan, E. M. M. M., Makis, W., & Rubio‐Casillas, A. (2023) · Vaccines · doi:10.3390/vaccines11050991 · Cited by 122 · see citing works
Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms
Champion, S. N., & Stone, J. R. (2019) · Modern Pathology · doi:10.1038/s41379-019-0363-0 · Cited by 115 · see citing works
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 112 · see citing works
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107 · see citing works
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 108 · see citing works
Co-stimulatory and co-inhibitory pathways in cancer immunotherapy
O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 101 · see citing works
Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 101 · see citing works
Chen, D., Huang, W., Wu, V. C., Chang, W., Chen, J., Chuang, C., & Chu, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.025 · Cited by 96 · see citing works
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 93 · see citing works
Xia, W., Zou, C., Chen, H., Xie, C., & Hou, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02778-2 · Cited by 88 · see citing works
T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword
Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 88 · see citing works
Yasuda, Y., Iwama, S., Sugiyama, D., Okuji, T., Kobayashi, T., Ito, M., Okada, N., Enomoto, A., Ito, S., Yan, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7495 · Cited by 87 · see citing works
Mascolo, A., Scavone, C., Ferrajolo, C., Rafaniello, C., Danesi, R., Re, M. D., Russo, A. D., Coscioni, E., Rossi, F., Alfano, R., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01086-8 · Cited by 82 · see citing works
Agrawal, N., Khunger, A., Vachhani, P. J., Colvin, T. A., Hattoum, A., Spangenthal, E. J., Curtis, A. B., Dy, G. K., Ernstoff, M. S., & Puzanov, I. J. (2019) · Case Reports in Oncology · doi:10.1159/000498985 · Cited by 80 · see citing works
Fatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab
Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 71 · see citing works
Immune checkpoint inhibitor-related myocarditis
Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 71 · see citing works
Martínez‐Calle, N., Rodríguez‐Otero, P., Villar, S., Mejías, L. D., Melero, I., Prósper, F., Marinello, P. M., Paiva, B., Idoate, M. A., & Miguel, J. F. S. (2018) · Haematologica · doi:10.3324/haematol.2017.185777 · Cited by 71 · see citing works
Wang, R., Singaraju, A., Marks, K. E., Shakib, L., Dunlap, G. S., Adejoorin, I., Greisen, S. R., Chen, L., Tirpack, A., Aude, C. A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1591 · Cited by 72 · see citing works
Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., Lorenzo, C. D., & Maurea, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040179 · Cited by 67 · see citing works
Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy
Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 64 · see citing works
Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy
de Almeida, D. V. P., Gomes, J. R., Haddad, F. J., & Buzaid, A. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000217 · Cited by 62 · see citing works
Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review
Pradhan, R., Nautiyal, A., & Singh, S. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.025 · Cited by 62 · see citing works
Chen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616505 · Cited by 59 · see citing works
Cardiotoxic mechanisms of cancer immunotherapy – A systematic review
Lobenwein, D., Kocher, F., Dobner, S., Gollmann‐Tepeköylü, C., & Holfeld, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.033 · Cited by 59 · see citing works
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55 · see citing works
Guo, C. W., Alexander, M., Dib, Y., Lau, P. K. H., Weppler, A. M., Au‐Yeung, G., Lee, B., Khoo, C. C. H., Mooney, D., Joshi, S. B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.009 · Cited by 55 · see citing works
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51 · see citing works
Nso, N., Antwi‐Amoabeng, D., Beutler, B. D., Ulanja, M. B., Ghuman, J., Hanfy, A. A., Nimo-Boampong, J., Atanga, S., Doshi, R. P., Enoru, S. T., et al. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i11.584 · Cited by 50 · see citing works
Berg, D. D., Vaduganathan, M., Davids, M. S., Alyea, E. P., Torre, M., Padera, R. F., & Nohria, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.806 · Cited by 49 · see citing works
Cardiotoxicities associated with immune checkpoint inhibitors
Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 49 · see citing works
Fan, Q., Hu, Y., Yang, C., & Zhao, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105866 · Cited by 48 · see citing works
Matzen, E., Bartels, L. E., Løgstrup, B. B., Madsen, S. H., Stilling, C., & Donskov, F. N. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00114-x · Cited by 45 · see citing works
Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
Shil, S., Kumar, P., & Mumbrekar, K. D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10531-0 · Cited by 55 · see citing works
Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy
Wang, W., & Cao, X. (2019) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2019031188 · Cited by 43 · see citing works
A Review of Immune-Mediated Adverse Events in Melanoma
Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 41 · see citing works
Kalinoski, H. M., Daoud, A. R., Rusinkevich, V., Jurčová, I., Talor, M. V., Welsh, R. A., Hughes, D., Zemanová, K., Střı́ž, I., Hooper, J. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2323052121 · Cited by 37 · see citing works
Therapeutic strategies for virus-negative myocarditis: a comprehensive review
Luca, G. D. D., Campochiaro, C., Sartorelli, S., Peretto, G., & Dagna, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.050 · Cited by 38 · see citing works
Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36 · see citing works
Huertas, R. M., Saavedra, C., Perna, C., Gómez, A. F., & Gordoa, T. A. (2019) · Cancer Management and Research · doi:10.2147/cmar.s185202 · Cited by 31 · see citing works
Hardy, T., Yin, M., Chavez, J. A., Ivanov, I., Chen, W., Nádasdy, T., & Brodsky, S. V. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107202 · Cited by 31 · see citing works
Hu, J., Tian, R., Ma, Y., Zhen, H., Ma, X., Su, Q., & Cao, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645245 · Cited by 31 · see citing works
Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835510 · Cited by 28 · see citing works
New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?
Barquín, A., Molina‐Cerrillo, J., Garrido, P., Garcia-Palos, D., Carrato, A., & Alonso‐Gordoa, T. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.020 · Cited by 27 · see citing works
Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature
Chauhan, A., Burkeen, G., Houranieh, J., Arnold, S. M., & Anthony, L. B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx213 · Cited by 27 · see citing works
Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy
Brumbaugh, A. D., Narurkar, R., Parikh, K., Fanucchi, M. P., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000217 · Cited by 26 · see citing works
Management of immune-related adverse events resulting from immune checkpoint blockade
Baroudjian, B., Arangalage, D., Cuzzubbo, S., Hervier, B., Lebbé, C., Lorillon, G., Tazi, A., Zalcman, G., Bouattour, M., Lioté, F., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1562342 · Cited by 28 · see citing works
Use of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 25 · see citing works
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 28 · see citing works
Zhao, S., Yun, H., Chen, C., Chen, Y., Lin, J., Zeng, M., Liu, T., Pan, C., & Jin, H. M. (2022) · European Radiology · doi:10.1007/s00330-022-08844-x · Cited by 24 · see citing works
Boutros, A., Bottini, A., Rossi, G., Tanda, E. T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., de Rosa, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100791 · Cited by 24 · see citing works
Matsuo, K., Ishiguro, T., Najama, T., Shimizu, Y., Kobayashi, Y., & Mutou, M. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2596-18 · Cited by 24 · see citing works
Zhang, C., Chen, Z., Qin, S., Zhu, Y., Shu, L., & Zuo, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1052699 · Cited by 19 · see citing works
Heart failure in cancer: role of checkpoint inhibitors
Delgobo, M., & Frantz, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.07 · Cited by 17 · see citing works
Manolis, A. S., Manolis, T. A., Mikhailidis, D. P., & Manolis, A. S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513488 · Cited by 17 · see citing works
Zarifa, A., Kim, J. W., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., & Kim, P. Y. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0089 · Cited by 17 · see citing works
Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 17 · see citing works
Somasundaram, A., & Burns, T. F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s105678 · Cited by 15 · see citing works
Immune Checkpoint Inhibitors–Related Cardiotoxicity
Konala, V. M., Adapa, S., & Aronow, W. S. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000988 · Cited by 15 · see citing works
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go
Vergara, A., Felice, M. D., Cesaro, A., Gragnano, F., Pariggiano, I., Golia, E., Pasquale, A. D., Blasi, E., Fimiani, F., Monda, E., et al. (2023) · Angiology · doi:10.1177/00033197231201929 · Cited by 15 · see citing works
Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
Zou, W., Lü, J., & Yan, H. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s311616 · Cited by 13 · see citing works
Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report
Sakai, T., Yahagi, K., Hoshino, T., Yokota, T., Tanabe, K., Mori, M., & Ikeda, S. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100839 · Cited by 13 · see citing works
Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis
Zhang, C., Qin, S., & Zuo, Z. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211027339 · Cited by 13 · see citing works
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065075 · Cited by 12 · see citing works
Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor‐Associated Myocarditis
Jo, W., Sun, V., & Čiháková, D. (2026) · Immunological Reviews · doi:10.1111/imr.70111 · Cited by 11 · see citing works
Immune-related adverse events of immune checkpoint inhibitors
Tadano, H., & Torigoe, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.102 · Cited by 11 · see citing works
Tedeschi, A., Camilli, M., Ammirati, E., Gentile, P., Palazzini, M., Conti, N., Verde, A., Masciocco, G., Foti, G., Giannattasio, C., et al. (2023) · Future Cardiology · doi:10.2217/fca-2022-0120 · Cited by 12 · see citing works
Nivolumab in squamous cell carcinoma of the head and neck
Specenier, P. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1456337 · Cited by 10 · see citing works
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma
Chang, A., Nasti, T. H., Khan, M. K., Parashar, S., Kaufman, J. L., Boise, L., Lonial, S., Ahmed, R., & Nooka, A. K. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00208 · Cited by 10 · see citing works
Zhao, S., Yun, H., Chen, C., Chen, Y., Lin, J., Zeng, M., Liu, T., Pan, C., & Jin, H. M. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110558 · Cited by 9 · see citing works
La myocardite : une toxicité rare mais grave sous immunothérapie
Courand, P., Bouali, A., Harbaoui, B., Cautela, J., Thuny, F., & Lantelme, P. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.09.003 · Cited by 9 · see citing works
Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8 · see citing works
Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis
Thakker, R. A., Lee, M. A., Albaeni, A., Elbadawi, A., Suthar, K. H., Perez, C., Sonstein, L. K., Farr, N. M., Venkatesan, R., Khalife, W. I., et al. (2021) · Cardiology Research · doi:10.14740/cr1319 · Cited by 9 · see citing works
Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response
Stefanovic, F., Gomez‐Caminero, A., Jacobs, D. M., Subramanian, P., Puzanov, I. J., Chilbert, M. R., Feuerstein, S. G., Yatsynovich, Y., Switzer, B., & Schentag, J. J. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s369008 · Cited by 8 · see citing works
Global epidemiology of myocarditis: disparities in age, sex and geography
Klingel, K., Tschöpe, C., Yon, D. K., Mensah, G. A., Weber, B. N., Kontorovich, A., Lee, S., Cooper, L. T., & Ammirati, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01276-w · Cited by 9 · see citing works
Duarte, T., Costa, C., Gonçalves, S., Raposo, L., Ferreira, A. M., Albuquerque, C., Vau, N., & Caria, R. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.013 · Cited by 7 · see citing works
Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review
Gul, R., Shehryar, M., Mahboob, A., Kareem, H. K., Inayat, A., Safi, D., & Kamran, A. S. (2024) · Cureus · doi:10.7759/cureus.52952 · Cited by 7 · see citing works
Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis
Arbune, A., Soufer, A., & Baldassarre, L. A. (2020) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-019-9521-5 · Cited by 6 · see citing works
An update on the safety of nivolumab for the treatment of advanced melanoma
Czarnecka, A. M., & Rutkowski, P. L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1757068 · Cited by 6 · see citing works
Gamero, M. T., Patel, A., & Storozynsky, E. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02147-x · Cited by 5 · see citing works
Papanikolopoulou, A., Michalopoulou, H., Kyriakoulis, K. G., Alexiou, P., Syrigos, N. K., Vathiotis, J., Thomopoulos, C., & Charpidou, A. G. (2025) · Cureus · doi:10.7759/cureus.87049 · Cited by 5 · see citing works
Chronic Anthracycline-related Myocarditis Presenting as Diffuse Myocardial Calcification
Pejic, M., Shifman, M., Rose, T. A., & Jeong, D. K. (2019) · Journal of Clinical Imaging Science · doi:10.25259/jcis_113_2019 · Cited by 5 · see citing works
What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications
Frayberg, M., Yung, A., Zubiri, L., Zlotoff, D. A., & Reynolds, K. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00844-1 · Cited by 5 · see citing works
Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis
Long, H., Du, Y., Wang, L., Liu, G.-C., Liang, S.-X., Zeng, Z., & Lin, Y.-E. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231216104 · Cited by 4 · see citing works
Immune Checkpoints and Their Inhibition in T-Cell Lymphomas
Seňavová, J., Rajmonová, A., Heřman, V., Jura, F., Velasova, A., Hamová, I., Tkachenko, A. S., Kupcová, K., & Havránek, O. (2024) · Folia Biologica · doi:10.14712/fb2024070030123 · Cited by 4 · see citing works
Tingry, T., Massy, E., Piperno, M., Auroux, M., Kostine, M., Maillet, D., Amini‐Adlé, M., Fabien, N., Estublier, C., Gonçalves, D., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.016 · Cited by 4 · see citing works
Ma, Y. N., Zhang, A., Lin, J. F., Ding, F., Wang, X., Wang, W., Jian, G., Zhang, J., Zhu, P., Ma, Y. N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102700 · Cited by 2 · see citing works
A case of sustained ventricular tachycardia due to pembrolizumab
Toyoshi, H., Yumoto, K., Yamanaka, K., Iwata, T., Koda, M., & Takatsu, H. (2019) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2019.08.009 · Cited by 2 · see citing works
Czarnecka, A. M., Kleibert, M., Płachta, I., Rogala, P., Wągrodzki, M., Leszek, P., & Rutkowski, P. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175182 · Cited by 2 · see citing works
Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: A case report
Alkhathlan, A. Z., Tofovic, D. S., Sullivan, C., Gupta, A., & Rajagopalan, S. (2017) · Case Reports in Internal Medicine · doi:10.5430/crim.v4n3p57 · Cited by 2 · see citing works
[Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu, Y., Chen, Y., Zeng, Z., & Liu, A. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.27 · Cited by 1 · see citing works
Myocarditis Induced by Immunotherapy: A Rare but Fatal Complication
Mulendelé, P. M., Njie, M., Charfo, M., Lukifimpa, G. M., Boutar, M. S., Ovaga, B. E., HABOUB, M., Arous, S., Benouna, M. G., Drighil, A., et al. (2023) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2023/v12i4360 · Cited by 1 · see citing works
- Authors
- Tadokoro, T., Keshino, E., Makiyama, A., Sasaguri, T., Ohshima, K., Katano, H., & Mohri, M.
- Affiliations
- Kurume University (JP)
- Venue
- Circulation: Heart Failure
- Published
- 2016-10
- Volume
- 9
- Issue
- 10
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2522075115
- Cited by
- 111
- References
- 4
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 10 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 12 · 2019: 22 · 2018: 14 · 2017: 10
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation Heart Failure (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
- Keywords
- nivolumab, anti-PD-1, drug-induced myocarditis, immune checkpoint inhibitors
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Acute Disease, Aged, Antibodies, Monoclonal, Biopsy, Choroid Neoplasms, Female, Glucocorticoids, Humans, Immunohistochemistry, Lymphocytosis, Melanoma, Myocarditis, Tomography, X-Ray Computed, Treatment Outcome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
